Literature DB >> 8252491

Infrequency of ras, p53, WT1, or RB gene alterations in Wilms tumors.

P G Waber1, J Chen, P D Nisen.   

Abstract

BACKGROUND: Alteration of the ras family of oncogenes and of the tumor suppressor genes p53 and RB are the most common genetic events in human tumors. Although there have been no reports of the prevalence of these alterations in Wilms tumors, overexpression of the N-myc and insulin-like growth factor-II (IGF-II) genes have been observed, and alteration of another tumor suppressor gene (WT1) has been demonstrated.
METHODS: Forty-four Wilms tumor specimens were tested for the presence of N-, K-, and H-ras mutations in codons 12, 13, and 61 by single-strand conformation polymorphism (SSCP) analysis and direct DNA sequence analysis. Sixteen tumors were tested for abnormalities of WT1 by Southern and northern blot analysis and reverse transcriptase polymerase chain reaction (RT-PCR). N-myc, c-myc, WT1, and IGF-II mRNA expression was measured in 16 tumors by Northern blot analysis. Thirty-eight tumors were screened for p53 mutations by SSCP analysis and direct DNA sequence analysis. Nine tumors were analyzed for loss of heterozygosity (LOH) of RB.
RESULTS: Although the authors confirmed that N-myc and IGF-II are overexpressed in Wilms tumors, no mutations of ras family, p53, or RB genes were identified, and no gross alterations of WT1 were detected by Southern or Northern blot analysis.
CONCLUSIONS: These findings suggest that H-ras, K-ras, N-ras, p53, and RB are not involved in the pathogenesis of Wilms tumor.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8252491     DOI: 10.1002/1097-0142(19931215)72:12<3732::aid-cncr2820721228>3.0.co;2-u

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Infrequency of p53 gene mutations in ependymomas.

Authors:  K L Fink; E J Rushing; S C Schold; P D Nisen
Journal:  J Neurooncol       Date:  1996-02       Impact factor: 4.130

Review 2.  Metanephric adenofibroma in a 10-year-old boy: report of a case and review of the literature.

Authors:  Dong-Wei Yao; Feng Qu; Su-Wei Hu; Jin-Yu Zheng; Jin-Mei Wang; Xiang-Yu Zhu; Jie Li; Hong-Qian Guo
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

3.  β-Catenin and K-RAS synergize to form primitive renal epithelial tumors with features of epithelial Wilms' tumors.

Authors:  Peter E Clark; Dina Polosukhina; Harold Love; Hernan Correa; Cheryl Coffin; Elizabeth J Perlman; Mark de Caestecker; Harold L Moses; Roy Zent
Journal:  Am J Pathol       Date:  2011-10-08       Impact factor: 4.307

4.  Immunohistochemical detection of p53 in Wilms' tumors correlates with unfavorable outcome.

Authors:  C Lahoti; P Thorner; D Malkin; H Yeger
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

5.  K-Ras, H-Ras, N-Ras and B-Raf mutation and expression analysis in Wilms tumors: association with tumor growth.

Authors:  Efterpi Dalpa; Victor Gourvas; Nikolaos Soulitzis; Demetrios A Spandidos
Journal:  Med Oncol       Date:  2016-12-09       Impact factor: 3.064

6.  PEA-15 potentiates H-Ras-mediated epithelial cell transformation through phospholipase D.

Authors:  F J Sulzmaier; M K G Valmiki; D A Nelson; M J Caliva; D Geerts; M L Matter; E P White; J W Ramos
Journal:  Oncogene       Date:  2011-11-21       Impact factor: 9.867

7.  Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors.

Authors:  Dina Polosukhina; Harold D Love; Hernan Correa; Zengliu Su; Kimberly B Dahlman; William Pao; Harold L Moses; Carlos L Arteaga; Harold N Lovvorn; Roy Zent; Peter E Clark
Journal:  Mol Oncol       Date:  2017-03-15       Impact factor: 6.603

8.  Failure to detect mutations in the retinoblastoma protein-binding domain of the transcription factor E2F-1 in human cancers.

Authors:  T Nakamura; Y Monden; K Kawashima; T Naruke; S Nishimura
Journal:  Jpn J Cancer Res       Date:  1996-12

9.  Wilms' tumour: Determinants of prognosis in an African setting.

Authors:  Akinfenwa Taoheed Atanda; Lofty-John Chuhwuemeka Anyanwu; Oladoyin Jareenat Atanda; Aminu Mohammad Mohammad; Lawal Barau Abdullahi; Aliyu Umar Farinyaro
Journal:  Afr J Paediatr Surg       Date:  2015 Jul-Sep
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.